In 2011, ‘Improving Outcomes: a strategy for cancer’ was published to raise awareness of the symptoms of cancer and further support earlier diagnosis. So, has progress been made. Quite naturally, policy makers as well as the public need to see how efficient these policies have been at addressing their aims.
Data and methods
To find out we used data from 3.5 m patients to look at the difference between the richest and the poorest patients surviving cancer and whether this has changed over time.
And this is what we found…
In 2013 more people are surviving cancer longer, but the deprivation gap still looks the same.
We believe the various policies and strategies have made a difference in some areas but not in reducing inequalities/the deprivation gap.
We recommend looking more closely at how the NHS interacts with the poorest and whether policies that target the health care system, rather than individual behavior, could reduce the inequalities.
Ninety four percent of pancreatic cancer patients die within 5 years of diagnosis. This is largely because patients tend not to experience obvious symptoms until the tumour is well advanced and there are no current means of screening. Research suggests that pancreatic cancer might be detectable via a blood test where no symptoms are present. However, this test would only be cost effective if given to patients at an increased risk of having pancreatic cancer.
In this project, funded by the Pancreatic Cancer Research Fund, we will use historic GP and hospital data to find out if it’s possible to identify patients who are most likely to have early stage pancreatic cancer. We will compare 3,115 people who were diagnosed with pancreatic cancer to a similar group of patients who were not. Using machine learning techniques, we will examine, for the first time, if there are combinations of particular health problems, illnesses, or symptoms experienced only by patients who are later diagnosed. Ultimately, improving the triage of these patients means that targeted diagnostic tests could lead to the pancreatic cancer being diagnosed earlier and treated more effectively.
Dr Laura Woods
Assistant Professor in Epidemiology
Laura completed her undergraduate degree in Human Sciences at Oxford University in 1999 and her Master’s degree in Medical Demography in 2001. She joined the Cancer Survival Group in September 2002 where she completed her PhD “International differences in breast cancer survival and ‘cure’ by social deprivation: a comparative study of England and Australia” in September 2006.
Prof Bernard Rachet
Professor of Cancer Epidemiology
Bernard qualified in medicine in France and worked as a clinician before entering epidemiological research. He completed a PhD in Epidemiology at the International Agency for Research on Cancer (IARC), Lyon, France. He joined LSHTM in 2002 and is currently principal investigator of a Cancer Research UK programme grant, leading a wide range of projects to quantify, describe and explain patterns and trends in cancer survival by socio-economic group, geographic area and ethnicity, as well as extending the methodology and tools for survival analysis, in collaboration with many research partners in the UK and around the world.